Head-To-Head Review: ADMA Biologics (NASDAQ:ADMA) & Cardiac Biotech Solutions (OTCMKTS:CBSC)

ADMA Biologics (NASDAQ:ADMA) and Cardiac Biotech Solutions (OTCMKTS:CBSC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Institutional and Insider Ownership

75.7% of ADMA Biologics shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares ADMA Biologics and Cardiac Biotech Solutions”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17 million	4.59	$146.93 million	$0.60	16.38
Cardiac Biotech Solutions	$140,000.00	42.54	N/A	N/A	N/A

ADMA Biologics has higher revenue and earnings than Cardiac Biotech Solutions.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ADMA Biologics and Cardiac Biotech Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	2	0	2	3.00
Cardiac Biotech Solutions	0	0	0	0	0.00

ADMA Biologics presently has a consensus price target of $32.00, suggesting a potential upside of 225.53%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than Cardiac Biotech Solutions.

Volatility and Risk

ADMA Biologics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Cardiac Biotech Solutions has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares ADMA Biologics and Cardiac Biotech Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	28.80%	37.52%	27.87%
Cardiac Biotech Solutions	N/A	N/A	N/A

Summary

ADMA Biologics beats Cardiac Biotech Solutions on 9 of the 11 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Cardiac Biotech Solutions

CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.